LFB Key Dates
January 1994 Creation of GIP LFB (public interest group) Pharmaceutical establishment
2006 GIP LFB becomes LFB SA, a majority State-owned limited company, with creation of LFB BIOMEDICAMENTS and LFB BIOTECHNOLOGIES, French subsidiaries.
2007 Acquisition of LFB BIOMANUFACTURING, formerly MABgène, in Alès (France).
2008 Signature of an industrial agreement with SANQUIN, a Dutch plasma-derived medicines manufacturer
2009
- French market authorizations for LFB liquid Ig 10% and LFB fibrinogen.
- Creation of US subsidiaries LFB USA and rEVO BIOLOGICS (formerly GTC BIOTHERAPEUTICS).
2010 :
- Acquisition of EUROPLASMA, specialized in plasma and blood collection.
- Creation of CELLforCURE subsidiary, specialized in advanced therapies – cell and gene therapies, the 1st technological platform for cell therapies in Europe.
2013 Launch of LFB GmbH, the German subsidiary
2014 :
- Launch of LFB BIOPHARMACEUTICALS subsidiary in United Kingdom.
2015:
- LFB S.A. increases its capital by 230 million euros
- Beginning of the construction of the LFB plant in Arras
- Creation of LFB BIOTERAPIAS HISPANIA subsidiary, in Spain
2016
- LFB becomes sole shareholder of CAF DCF in Belgium
- Inauguration of new industrial facilities (UP2) at LFB BIOMANUFACTURING
2017 :
- LFB’s fibrinogen and 10% immunoglobulin authorized for use in Europe
- Denis Delval is appointed CEO of LFB S.A
- Distribution agreement signed in Mexico with LFB MEXICO joint venture
2018 New strategy for LFB Group
2019 LFB strategic transformation: refocusing on LFB core business, medicinal products derived from plasma or recombinant proteins
2020 SEVENFACT® approval in the USA.
2022
2023
Doubling of LFB’S BIOPRODUCTION CAPACITY AT ALÈS WITH THE SUPPORT OF “FRANCE 2030”
